[go: up one dir, main page]

UA83791C2 - Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 - Google Patents

Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1

Info

Publication number
UA83791C2
UA83791C2 UA20031110207A UA20031110207A UA83791C2 UA 83791 C2 UA83791 C2 UA 83791C2 UA 20031110207 A UA20031110207 A UA 20031110207A UA 20031110207 A UA20031110207 A UA 20031110207A UA 83791 C2 UA83791 C2 UA 83791C2
Authority
UA
Ukraine
Prior art keywords
vla
mediated
antibody
pharmaceutical composition
immunological disorder
Prior art date
Application number
UA20031110207A
Other languages
English (en)
Ukrainian (uk)
Inventor
Пол Д. Лайн
Эллен А. Гарбер
Хосе В. Салдана
Майкл Карпусас
Original Assignee
Байоджен Айдек Ма Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Байоджен Айдек Ма Инк. filed Critical Байоджен Айдек Ма Инк.
Publication of UA83791C2 publication Critical patent/UA83791C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)

Abstract

Изобретение относится к антителу против интегрина VLA-1, которое имеет уникальные гипервариабельные участки (CDR), выделенной последовательности нуклеиновой кислоты, которая его кодирует, вектору, клетки гибридомы и клетке клеточной линии, фармацевтической композиции, способу лечения индивидуума с иммунологическим расстройством, опосредованным VLA-1, способу определения уровня VLA-1 в ткани. Изобретение также относится к химерному и гуманизированному антителу против VLA-1.
UA20031110207A 2001-04-13 2002-04-12 Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1 UA83791C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28379401P 2001-04-13 2001-04-13
US30368901P 2001-07-06 2001-07-06
PCT/US2002/011521 WO2002083854A2 (en) 2001-04-13 2002-04-12 Antibodies to vla-1

Publications (1)

Publication Number Publication Date
UA83791C2 true UA83791C2 (ru) 2008-08-26

Family

ID=26962254

Family Applications (1)

Application Number Title Priority Date Filing Date
UA20031110207A UA83791C2 (ru) 2001-04-13 2002-04-12 Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1

Country Status (29)

Country Link
US (7) US7358054B2 (ru)
EP (1) EP1423431B1 (ru)
JP (2) JP4303475B2 (ru)
KR (1) KR100927670B1 (ru)
CN (1) CN1561345B (ru)
AR (1) AR036330A1 (ru)
AT (1) ATE471344T1 (ru)
AU (1) AU2002258778C1 (ru)
BG (1) BG66334B1 (ru)
BR (1) BRPI0209792B8 (ru)
CA (1) CA2443903C (ru)
CZ (1) CZ303450B6 (ru)
DE (1) DE60236735D1 (ru)
EA (1) EA006705B1 (ru)
EE (1) EE200300509A (ru)
ES (1) ES2347532T3 (ru)
GE (1) GEP20074252B (ru)
HU (1) HUP0402250A3 (ru)
IL (3) IL158376A0 (ru)
IS (1) IS6982A (ru)
MX (1) MXPA03009390A (ru)
MY (1) MY138286A (ru)
NO (1) NO20034554L (ru)
NZ (1) NZ529494A (ru)
PL (1) PL367324A1 (ru)
SK (1) SK288124B6 (ru)
UA (1) UA83791C2 (ru)
WO (1) WO2002083854A2 (ru)
YU (1) YU80903A (ru)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
HK1043320A1 (zh) 1999-06-01 2002-09-13 Biogen, Inc. Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用
PL367324A1 (en) 2001-04-13 2005-02-21 Biogen, Inc. Antibodies to vla-1
KR101098109B1 (ko) 2002-03-13 2011-12-26 더 리전츠 오브 더 유니버시티 오브 캘리포니아 항αｖβ6 항체
CA2554753A1 (en) * 2004-01-29 2005-08-11 National Institute Of Advanced Industrial Science And Technology Composition and method for elevating gene transfer efficiency
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
WO2006124269A2 (en) * 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) * 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
CN102875681A (zh) 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
WO2007114319A1 (ja) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 抗体の血中動態を制御する方法
US9670269B2 (en) * 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
AU2013204572B2 (en) * 2006-05-25 2015-06-18 Biogen Ma Inc. Methods of Treating Stroke
EP2034830B1 (en) * 2006-05-25 2014-09-03 Biogen Idec MA Inc. Anti-vla-1 antibody for treating stroke
JP2009542810A (ja) 2006-07-10 2009-12-03 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｓｍａｄ４欠損癌の増殖を阻害するための組成物および方法
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
EP2031064A1 (de) * 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
EP3127921A1 (en) * 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CN101874041B (zh) * 2007-09-26 2013-06-19 中外制药株式会社 抗体恒定区修饰体
TWI548418B (zh) 2007-12-05 2016-09-11 Chugai Pharmaceutical Co Ltd Anti-NR10 / IL-31RA antibody and its use
EP2708559B1 (en) * 2008-04-11 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
CN102245207B (zh) * 2008-11-13 2015-11-25 费塔制药股份有限公司 人源化抗il-6抗体
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
EP3674317B1 (en) 2009-03-19 2024-12-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
CN102459344A (zh) 2009-05-15 2012-05-16 中外制药株式会社 抗axl抗体
US10150808B2 (en) 2009-09-24 2018-12-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant regions
PE20121542A1 (es) * 2009-10-23 2012-12-06 Millennium Pharm Inc Moleculas de anticuerpo anti-gcc y composiciones y metodos relacionados
EP2543730B1 (en) 2010-03-04 2018-10-31 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
HRP20180421T1 (hr) 2010-11-17 2018-04-20 Chugai Seiyaku Kabushiki Kaisha Višestruko specifične molekule za vezanje na antigen koje imaju alternativnu funkciju u odnosu na funkciju faktora viii zgrušavanja krvi
TWI654204B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
US20140017261A1 (en) * 2011-02-03 2014-01-16 Mark Totoritis Selection and treatment of subjects
IL269687B (en) 2011-02-10 2022-08-01 Roche Glycart Ag Interleukin-2 polypeptides
WO2012115241A1 (ja) 2011-02-25 2012-08-30 中外製薬株式会社 FcγRIIb特異的Fc抗体
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
TW201817744A (zh) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 具有促進抗原清除之ＦｃＲｎ結合域的治療性抗原結合分子
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
MX370199B (es) * 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).
MY188442A (en) 2012-04-27 2021-12-09 Millennium Pharm Inc Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
CN108503711A (zh) 2012-04-30 2018-09-07 比奥孔有限公司 靶向/免疫调节性融合蛋白及其制造方法
RS62509B1 (sr) 2012-07-13 2021-11-30 Roche Glycart Ag Bispecifična anti-vegf/anti-ang-2 antitela i njihova upotreba u lečenju očnih vaskularnih bolesti
CA2902830C (en) 2013-03-12 2023-09-19 Biocon Ltd. Fusion immunomodulatory proteins and methods for making same
US10035859B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
US10035860B2 (en) 2013-03-15 2018-07-31 Biogen Ma Inc. Anti-alpha V beta 6 antibodies and uses thereof
RU2730594C2 (ru) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Способ получения полипептидного гетеромультимера
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
ES2899894T3 (es) 2014-12-19 2022-03-15 Chugai Pharmaceutical Co Ltd Anticuerpos anti-C5 y métodos de uso
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2017008978A (es) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Anticuerpos que comprenden un dominio de union al antigeno dependiente de la concentracion ionica, variantes de la region fc, antiocuerpor de union a interleucina 8 (il-8) y usos de los mismos.
ES2967627T3 (es) 2015-02-27 2024-05-03 Chugai Pharmaceutical Co Ltd Composición para tratar enfermedades relacionadas con IL-6
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
AU2017233658B2 (en) 2016-03-14 2023-09-21 Chugai Seiyaku Kabushiki Kaisha Cell injury inducing therapeutic drug for use in cancer therapy
MA44780A (fr) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd Préparation contenant un anticorps
TWI831965B (zh) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
MA49645A (fr) * 2017-07-20 2021-03-31 Univ Virginia Patent Foundation Procédés de traitement ou de prévention d'un trouble neurologique du système immunitaire
MA50534A (fr) 2017-11-01 2020-09-09 Chugai Pharmaceutical Co Ltd Variant d'anticorps et isoforme à activité biologique réduite
WO2019177543A1 (en) 2018-03-15 2019-09-19 Chugai Seiyaku Kabushiki Kaisha Anti-dengue virus antibodies having cross-reactivity to zika virus and methods of use
MA54052A (fr) 2018-10-29 2022-02-09 Hoffmann La Roche Formulation d'anticorps
EP3911363A1 (en) * 2019-01-14 2021-11-24 University of Virginia Patent Foundation Use of integrin inhibitors for treatment or prevention of a neurological immunity disorder and/or nervous system injury
EP4017542A1 (en) 2019-10-04 2022-06-29 Tae Life Sciences Antibody compositions comprising fc mutations and site-specific conjugation properties
GB2595299B (en) 2020-05-21 2022-08-03 Mabsolve Ltd Modified immunoglobulin FC regions

Family Cites Families (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5391481A (en) 1990-08-31 1995-02-21 The Trustees Of Columbia University Antibody which is directed against and inhibits collagen binding to a VLA-1 epitope and uses thereof
US5871907A (en) 1991-05-15 1999-02-16 Medical Research Council Methods for producing members of specific binding pairs
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
JPH07506091A (ja) 1992-01-13 1995-07-06 バイオゲン　インコーポレイテッド 喘息の処置
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6307026B1 (en) 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
WO1994016094A2 (en) 1993-01-12 1994-07-21 Biogen, Inc. Recombinant anti-vla4 antibody molecules
AU687790B2 (en) 1993-02-09 1998-03-05 Biogen Idec Ma Inc. Treatment for insulin dependent diabetes
US6111598A (en) 1993-11-12 2000-08-29 Peveo, Inc. System and method for producing and displaying spectrally-multiplexed images of three-dimensional imagery for use in flicker-free stereoscopic viewing thereof
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
DE69535133T2 (de) 1994-01-25 2008-08-21 Elan Pharmaceuticals, Inc., San Francisco Humanisierte antikörper gegen das leukozytenadhäsionsmolekül vla-4
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
DE69518415T2 (de) 1994-04-26 2001-01-25 Kanebo, Ltd. Arznei für rheumatoide arthritis
JPH08131185A (ja) 1994-11-14 1996-05-28 Sumitomo Electric Ind Ltd マウスｖｌａ−１分子に対するモノクローナル抗体
JPH08160972A (ja) 1994-12-01 1996-06-21 Sega Enterp Ltd エフェクト制御方法、制御装置およびこれを利用したカラオケ装置
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
GB9516399D0 (en) 1995-08-10 1995-10-11 Camelot Superabsorbents Ltd Process for the production of water-absorbing compositions
ES2176484T3 (es) 1995-08-18 2002-12-01 Morphosys Ag Bancos de proteinas/(poli)peptidos.
KR100308764B1 (ko) 1995-08-29 2001-12-17 마나배게이사꾸 키메라동물및그의제작법
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
GB9519667D0 (en) 1995-09-27 1995-11-29 Univ Manchester Pharmaceutical composition
DE19541844C1 (de) 1995-11-09 1997-07-24 Gsf Forschungszentrum Umwelt Verfahren zur Herstellung von menschlichen Antikörpern und deren Verwendung
US6127524A (en) 1996-10-18 2000-10-03 Dade Behring Inc. Binding molecules and computer-based methods of increasing the binding affinity thereof
DK1500329T3 (da) 1996-12-03 2012-07-09 Amgen Fremont Inc Humane antistoffer, der specifikt binder TNF-alfa
DE69810481T2 (de) 1997-06-13 2003-09-25 Genentech Inc., San Francisco Stabilisierte antikörperformulierung
DE69935853T2 (de) 1998-05-22 2008-01-10 Boys Town National Research Hospital, Omaha Anwendung von alfa1beta1 integrinrezeptorinhibitoren und tgf-beta1-inhibitoren zur behandlung von nierenkrankheiten
DE19831710A1 (de) 1998-07-15 2000-01-20 Merck Patent Gmbh Diacylhydrazinderivate
WO2000020459A1 (en) 1998-10-06 2000-04-13 Biogen, Inc. Crystals of the alpha 1 beta 1 integrin i-domain and their use
EP1173201B1 (en) * 1999-04-22 2005-06-22 Biogen Idec MA Inc. Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
HK1043320A1 (zh) * 1999-06-01 2002-09-13 Biogen, Inc. Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用
AU4545600A (en) 1999-06-17 2001-01-09 Kai Desinger Surgical, grooved director for collecting tissue in a minimally invasive manner
WO2001073444A2 (en) 2000-03-28 2001-10-04 Cambridge University Technical Services Limited Receptor/peptide crystal structure for identification of inhibitors
US8288322B2 (en) 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
DE10028402A1 (de) 2000-06-13 2001-12-20 Merck Patent Gmbh Pyridin-2-yl-aminoalkycarbonylglycyl-beta-alanin und Derivate
US7153944B2 (en) 2000-07-31 2006-12-26 The General Hospital Corporation High affinity integrin polypeptides and uses thereof
PL367324A1 (en) 2001-04-13 2005-02-21 Biogen, Inc. Antibodies to vla-1
AU2003215298A1 (en) 2002-02-14 2003-09-04 Biogen, Inc. Alpha1beta1 antagonists for treatment of atherosclerosis
CA2494310A1 (en) 2002-08-01 2004-02-12 Immunomedics, Inc. Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
US20040208870A1 (en) 2003-01-30 2004-10-21 Medimmune, Inc. Stabilized high concentration anti-integrin alphanubeta3 antibody formulations
WO2005019200A2 (en) 2003-08-14 2005-03-03 Icos Corporation Aryl piperidine derivatives as vla-1 integrin antagonists and uses thereof
WO2005019177A1 (en) 2003-08-14 2005-03-03 Icos Corporation Aminopiperidine amide derivatives as vla-1 integrin antagonists and uses thereof
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
WO2006124269A2 (en) 2005-05-16 2006-11-23 Amgen Fremont Inc. Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
WO2006133286A2 (en) 2005-06-07 2006-12-14 Tel Hashomer Medical Research Infrastructure And Services Ltd. Treatment of tnf antagonist-resistant inflammatory disorders and related methods
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20080118496A1 (en) 2006-04-10 2008-05-22 Medich John R Uses and compositions for treatment of juvenile rheumatoid arthritis
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP2034830B1 (en) 2006-05-25 2014-09-03 Biogen Idec MA Inc. Anti-vla-1 antibody for treating stroke
JP4951596B2 (ja) 2008-07-31 2012-06-13 株式会社日立製作所 冷却システム及び電子装置
CN102414221A (zh) 2009-03-06 2012-04-11 健泰科生物技术公司 抗体配制剂
ES2765657T3 (es) 2009-12-21 2020-06-10 Hoffmann La Roche Formulación farmacéutica de bevacizumab
US20140017261A1 (en) 2011-02-03 2014-01-16 Mark Totoritis Selection and treatment of subjects
US9018035B2 (en) 2012-01-11 2015-04-28 Panasonic Intellectual Property Management Co., Ltd. Pressed-contact type semiconductor device and method for manufacturing the same
MX370199B (es) 2012-02-16 2019-12-05 Santarus Inc Composiciones farmaceuticas de anticuerpo anti-antigeno muy tardio (cd49a).

Also Published As

Publication number Publication date
CN1561345A (zh) 2005-01-05
US20090010930A1 (en) 2009-01-08
US10336826B2 (en) 2019-07-02
JP4303475B2 (ja) 2009-07-29
EP1423431A2 (en) 2004-06-02
PL367324A1 (en) 2005-02-21
JP2009079047A (ja) 2009-04-16
US9644030B2 (en) 2017-05-09
MXPA03009390A (es) 2004-01-29
BR0209792A (pt) 2005-04-26
CN1561345B (zh) 2011-09-14
DE60236735D1 (de) 2010-07-29
NZ529494A (en) 2005-08-26
BG108340A (bg) 2004-10-29
BG66334B1 (bg) 2013-06-28
IL158376A0 (en) 2004-05-12
IL158376A (en) 2011-07-31
CZ20033039A3 (cs) 2004-03-17
US7358054B2 (en) 2008-04-15
EP1423431B1 (en) 2010-06-16
ATE471344T1 (de) 2010-07-15
EE200300509A (et) 2004-08-16
AR036330A1 (es) 2004-09-01
EA200301117A1 (ru) 2004-08-26
EP1423431A4 (en) 2005-04-27
JP2004536580A (ja) 2004-12-09
ES2347532T3 (es) 2010-11-02
US20040081651A1 (en) 2004-04-29
US8084028B2 (en) 2011-12-27
SK288124B6 (sk) 2013-09-03
US20100272716A1 (en) 2010-10-28
IL213564A0 (en) 2011-07-31
WO2002083854A3 (en) 2004-04-08
AU2002258778C1 (en) 2008-12-04
CA2443903A1 (en) 2002-10-24
GEP20074252B (en) 2007-12-10
EA006705B1 (ru) 2006-02-24
NO20034554L (no) 2003-12-15
US7910099B2 (en) 2011-03-22
CA2443903C (en) 2018-03-20
BRPI0209792B8 (pt) 2021-05-25
WO2002083854A2 (en) 2002-10-24
KR20040062879A (ko) 2004-07-09
YU80903A (sh) 2006-05-25
AU2002258778A2 (en) 2002-10-28
SK13742003A3 (sk) 2004-07-07
AU2002258778B2 (en) 2008-01-17
KR100927670B1 (ko) 2009-11-20
NO20034554D0 (no) 2003-10-10
MY138286A (en) 2009-05-29
US20120177638A1 (en) 2012-07-12
HUP0402250A3 (en) 2007-06-28
US20110189177A1 (en) 2011-08-04
US7723073B2 (en) 2010-05-25
IL213564B (en) 2018-06-28
IS6982A (is) 2003-10-08
US20170335000A1 (en) 2017-11-23
CZ303450B6 (cs) 2012-09-19
US20150299323A1 (en) 2015-10-22
HUP0402250A2 (hu) 2005-01-28
WO2002083854A9 (en) 2003-11-06
BRPI0209792B1 (pt) 2017-03-28

Similar Documents

Publication Publication Date Title
UA83791C2 (ru) Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
WO2005000901A3 (en) Cd20-specific antibodies and methods of employing same
SG155883A1 (en) Anti-cd3 antibodies and methods of use thereof
TW200716182A (en) Antibodies directed to CD20 and uses thereof
TW200716677A (en) Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
TW200634027A (en) Antibodies directed to angiopoietin-2 and uses thereof
EP1578799A4 (en) ANTIBODIES THAT AFFECT TUMOR NECROSIS FACTOR (TNF) AND THEIR USE
TW200637873A (en) Antibodies against interleukin-1 beta
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
MXPA01010739A (es) Anticuerpos especificos y fragmentos de anticuerpo para el factor de crecimiento transformante beta-1.
BR0110927A (pt) Anticorpo, ácido nucléico, vetor, célula, método de fabricar um anticorpo, composição farmacêutica, uso de um anticorpo ou de um ácido nucleico, e, método para o tratamento ou profilaxia do câncer
WO2004029092A8 (fr) Anticorps pour adcc et induisant la production de cytokines.
NZ590863A (en) Anti-hepcidin-25 selective antibodies and uses thereof
WO1998050433A3 (en) Human monoclonal antibodies to epidermal growth factor receptor
WO2003057857A3 (en) Antibodies directed to pdgfd and uses thereof
TW200801040A (en) Binding proteins specific for insulin-like growth factors and uses thereof
NZ602780A (en) Human antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof
WO2008112004A3 (en) ANTIBODIES DIRECTED TO αVβ6 AND USES THEREOF
WO2003052082A3 (en) Fusion partner cells and uses thereof
IL162117A0 (en) Humanized collagen antibodies and methods utilizing the same
MX2022010665A (es) Anticuerpos que se unen al receptor de interleucina 4 (il4r) y usos de los mismos.
GR3022847T3 (en) Monoclonal antibodies
PH12022552520A1 (en) Antibodies binding siglec15 and uses thereof
ZA202308896B (en) Antibodies binding trop2 and uses thereof
WO2002094853A3 (en) Antibodies specific for poly(ethylene glycol)